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ABSTRACT
Objectives: To describe secular trends in
Staphylococcus aureus bacteraemia (SAB) and to
assess the impacts of infection control practices,
including universal methicillin-resistant
Staphylococcus aureus (MRSA) admission screening
on associated clinical burdens.
Design: Retrospective cohort study and multivariate
time-series analysis linking microbiology, patient
management and health intelligence databases.
Setting: Teaching hospital in North East Scotland.
Participants: All patients admitted to Aberdeen Royal
Inﬁrmary between 1 January 2006 and 31 December
2010: n¼420452 admissions and 1430052 acute
occupied bed days (AOBDs).
Intervention: Universal admission screening
programme for MRSA (August 2008) incorporating
isolation and decolonisation.
Primary and secondary measures: Hospital-wide
prevalence density, hospital-associated incidence
density and death within 30 days of MRSA or methicillin-
sensitive Staphylococcus aureus (MSSA) bacteraemia.
Results: Between 2006 and 2010, prevalence density
of all SAB declined by 41%, from 0.73 to 0.50 cases/
1000 AOBDs (p¼0.002 for trend), and 30-day
mortality from 26% to 14% (p¼0.013). Signiﬁcant
reductions were observed in MRSA bacteraemia only.
Overnight admissions screened for MRSA rose from
43% during selective screening to >90% within
4 months of universal screening. In multivariate time-
series analysis (R
2 0.45 to 0.68), universal screening
was associated with a 19% reduction in prevalence
density of MRSA bacteraemia ( 0.035, 95% CI
 0.049 to  0.021/1000 AOBDs; p<0.001), a 29% fall
in hospital-associated incidence density ( 0.029, 95%
CI  0.035 to  0.023/1000 AOBDs; p<0.001) and
a 46% reduction in 30-day mortality ( 15.6, 95% CI
 24.1% to  7.1%; p<0.001). Positive associations
with ﬂuoroquinolone and cephalosporin use suggested
that antibiotic stewardship reduced prevalence density
of MRSA bacteraemia by 0.027 (95% CI 0.015 to
0.039)/1000 AOBDs. Rates of MSSA bacteraemia were
not signiﬁcantly affected by screening or antibiotic use.
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ARTICLE SUMMARY
Article focus
- This study describes the changing epidemiology of
MRSA and MSSA bacteraemia in a large inpatient
population from Scotland over a 5-year period.
- Second, it evaluates the impact of universal
MRSA admission screening, and other infection
control practices, on hospital-wide rates of
MRSA bacteraemia.
Key messages
- Recent declines in clinical burdens from SAB in
North East Scotland were attributable to a reduc-
tion in invasive MRSA infections.
- Compared with a strategy of targeted screening
in high-risk environments, universal admission
screening may signiﬁcantly reduce rates of
MRSA bacteraemia and associated early
mortality alongside improvements in antibiotic
stewardship and infection control.
- Strategies to reduce clinical burdens from MSSA
bacteraemia are required if progress towards
national targets for all SAB is to be sustained.
Strengths and limitations of this study
- Without a contemporary control, this study did
not prove causality but a temporal association
between universal admission screening and rates
of MRSA bacteraemia.
- ARIMA modelling accounted for the non-inde-
pendence of data and stochastic elements in time
series of infections, and the dynamic effects of
changes in other aspects of care.
- Findings may be limited to large public hospitals
with intensive care units and endemic MRSA but
low rates of MRSA infection.
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Open Access ResearchConclusions: Declining clinical burdens from SAB were attributable
to reductions in MRSA infections. Universal admission screening and
antibiotic stewardship were associated with decreases in MRSA
bacteraemia and associated early mortality. Control of MSSA
bacteraemia remains a priority.
INTRODUCTION
Staphylococcus aureus is an important cause of serious,
invasive and healthcare-associated infections worldwide.
1
In high-income countries, it remains a leading cause of
community and nosocomial bacteraemia,
2 associated
with mortality rates of 20%e50%
34and large economic
burdens.
5 In the UK, dramatic increases in Staphylococcus
aureus bacteraemia (SAB) during the 1990s were attrib-
uted to methicillin-resistant Staphylococcus aureus
(MRSA)
36and healthcare exposures,
7 engendering
aggressive public health responses.
8 A decade of national
mandatory surveillance of both methicillin-sensitive
Staphylococcus aureus (MSSA) and MRSA bacteraemia has
suggested impacts from infection control measures,
91 0
but there remain over 12000 cases annually.
11 12
Despite a steep reduction in MRSA bacteraemia
from a peak in 2003/2004, rates of MSSA bacteraemia
have remained relatively stable.
11 12 Reasons for this
MRSA-speciﬁc decline are not fully understood.
91 0
Meanwhile, studies assessing the importance of methi-
cillin resistance to outcomes after SAB have yielded
conﬂicting results.
341 3 e18 These uncertainties are
reﬂected in different public health approaches: England
and Wales implemented performance targets for
reducing MRSA bacteraemia only,
9 while NHS Scotland’s
strategy aimed to reduce all SAB to 70% of 2005/2006
levels by 2010.
19 Some authors have warned that policy
focusing on MRSA alone may have unintended adverse
effects on control of MSSA.
20 It is therefore important to
understand the evolving epidemiology of both MRSA
and MSSA bacteraemia.
21
UK policy on reducing burdens from MRSA has
advocated admission screening, with subsequent
decolonisation and isolation, despite weaknesses in
evidence.
22e25 Studies on MRSA screening have gener-
ally assessed impacts on bacteraemia by surveillance in
high-risk groups,
26 27 while studies of universal surveil-
lance have taken all MRSA infections as the primary
outcome.
25 28 In 2008, a universal screening strategy was
piloted in three NHS Scotland trusts,
29 30 providing an
opportunity to assess effects on rates of MRSA bacter-
aemia, compared with a previous strategy of selective
screening in high-risk environments.
This study aimed to describe the changing clinical
epidemiology of SAB in a large inpatient population
over a 5-year period and to evaluate the impact of
infection control measures, including universal MRSA
admission screening. Our prespeciﬁed null hypothesis
was that universal screening would not signiﬁcantly
reduce rates of MRSA bacteraemia, after accounting for
prior trends and changes in other aspects of care in
time-series intervention analysis.
METHODS
Study design
This retrospective cohort study described secular trends
in SAB in all admissions to Aberdeen Royal Inﬁrmary
(ARI) between 2006 and 2010. A quasi-experimental
before-and-after design used time-series data from the
same period to assess the impact of introducing
universal admission surveillance on MRSA bacteraemia
alongside other infection control practices (ﬁgure 1).
Controls were historic trends in MRSA bacteraemia and
concurrent trends in MSSA bacteraemia.
Setting
ARI is a tertiary referral centre and acute teaching hospital
(1000 beds, 85000 annual admissions), serving a popula-
tion of 500000 in North East Scotland (NHS Grampian). It
provides a full range of acute medical and surgical services,
with a 16-bedded intensive care unit (ICU) (800 admis-
sions/year) and a cardiac ICU (six beds, 600 admissions/
year). Microbiology services also serve the on-site 185-
bedded maternity and 85-bedded children’s hospitals.
Admission screening intervention
Universal admission screening for MRSA was introduced
in NHS Grampian in August 2008 as part of an NHS
Scotland Pathﬁnder Project detailed elsewhere.
29 30 This
32-month pilot study (ending March 2011) tested
a strategy suggested as most clinically and cost-effective
by an NHS Scotland Health Technology Assessment
(supplemental ﬁle 1).
29 This involved screening of all
overnight admissions to acute specialities (excluding
obstetrics, paediatrics and psychiatry) by nasal (and
wound or device as necessary) swabs, isolation or
cohorting of all patients with known or new colonisation
or infection with MRSA and decolonising of all MRSA-
positive patients admitted to any specialty. Decolonisa-
tion therapy included 5 days of daily body wash with 4%
chlorhexidine gluconate and thrice-daily mupirocin
nasal ointment. Patients were re-swabbed a minimum of
2 days after decolonisation and could be removed from
isolation on receipt of three successive negative swabs,
taken $48 h apart. Elective patients were screened at
preadmission assessment or on admission. Compliance
with screening and infection control protocols was
monitored. Prior to the intervention, MRSA screening
was performed on selected high-risk patients only,
including intensive care and elective surgical admissions,
with an identical strategy of isolation and decolonisation.
Outcomes and potential confounders
SAB was deﬁned as the isolation of any S aureus from $1
blood culture bottle. Cultures from the same patient
within 14 days of the original isolate were considered to
represent the same episode. Patients could be included
more than once in analysis for different episodes.
Hospital-associated (HA) bacteraemia was deﬁned as
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admission or within 14 days of discharge, without history
of bacteraemia or MRSA colonisation or infection.
The primary outcome measure was prevalence density
of MRSA and MSSA bacteraemia. Secondary outcomes are
detailed in ﬁgure 1. Secular trends in longer term
outcomes were also investigated with recurrence
expressed as episodes per 1000 patient-months to avoid
follow-up bias.
In examining secular trends and the impacts of
universal MRSA admission screening, we considered
changes in other aspects of care and case-mix including:
MRSA importation pressure (No. of patients who are
MRSA positive or with a history of MRSA at admission/
1000 acute occupied bed days (AOBDs)) length of stay,
3 13
bed occupancy,
7 patient age,
341 3admitting department,
3
hand hygiene
93 2 e35 and antibiotic usage.
34e37 We
considered the effects of other hospital-wide infection
control measures with potential to affect MRSA including:
a national hand-hygiene campaign (January 2007); and
a mixed persuasive and restrictive antibiotic stewardship
intervention (May 2009), limiting use of antibiotics
associated with Clostridium difﬁcile and resistant gram-
positive or gram-negative infections (ﬁgure 1 and
supplemental ﬁle 2).
Study population
All patients admitted to medical, surgical, paediatric and
maternity services at ARI between 1 January 2006 and 31
December 2010 were eligible for inclusion in the study.
This period was chosen as it included the time frame
stated in national targets for reducing rates of SAB. A
time series of 60 months with equivalent baseline and
intervention periods (31 and 29 months) also facilitated
a robust time-series analysis.
38 Outpatients in all speci-
alities were excluded. Admissions resulting in death or
discharge within 24 h were retained in the main analysis
so as to capture burdens from community-associated
bacteraemia. Patients at risk of incident HA bacteraemia
were those hospitalised for at least 48 h without previous
documented SAB. Follow-up was until inhospital death,
180 days from bacteraemia or a minimum of 2 weeks
after discharge (whichever was longest) and ended on 15
June 2011.
Data collection
Electronic laboratory records were screened to identify
admission screening swabs, previous or current MRSA
colonisation or infection, episodes of SAB and location
of sampling. Patient identiﬁers were used to identify
multiple samples from the same patient.
Figure 1 Study overview in
accordance with the ORION
(Outbreak Reports and
Intervention Studies Of
Nosocomial infection)
statement.
31 *‘4C’ antibiotics are
clindamycin, ciproﬂoxacin (all
ﬂuoroquinolones), cephalosporins
(all generations), co-amoxiclav.
AOBDs, acute occupied bed days;
ICD, infection control doctor; ICN,
infection control nurse; ICU,
intensive care unit; MRSA,
methicillin-resistant
Staphylococcus aureus; SAB,
Staphylococcus aureus
bacteraemia; WTE, whole-time
equivalents calculated as 37.5 h/
week352 weeks ¼1950 h/year.
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Universal MRSA admission screening and Staphylococcus aureus bacteraemiaHealth intelligence databases provided data on
demographics, admission details and mortality for all
admissions between 2006 and 2010. Aggregated data on
bed occupancy were also provided by month and
department. For episodes of bacteraemia, data were
triangulated using the hospital’s Patient Management
System. Numbers of admissions within the last
12 months and age were taken as a proxy of patients’
baseline health.
Details on use of ‘4C’ (ciproﬂoxacin, cephalosporins,
clindamycin, co-amoxiclav) and macrolide antibiotics
(deﬁned daily doses/1000 AOBDs) and hand hygiene
(litres of alcohol gel used/1000 AOBDs; monthly average
hand-hygiene compliance assessed by nationally stand-
ardised audit of opportunity and technique) were ascer-
tained from pharmacy and infection control departments.
Use of routinely collected data meant an almost
complete data set. Data on outcomes after discharge
were missing for six patients (0.7%) with SAB and for
obstetric or neonatal inpatients without bacteraemia.
Outcomes were explored using a complete-case analysis
or departments with complete data.
Laboratory methods
Screening swabs were tested by latex slide test after
plating on chromogenic agar (BrillianceeOxoid,
Basingstoke, UK), followed by conﬁrmatory coagulase
test. Antibiotic sensitivities were evaluated by disc-diffu-
sion test. Processing of screening and clinical samples
was carried out 24 h a day, 7 days a week. After conﬁr-
mation by laboratory staff, results were made immedi-
ately available on an electronic laboratory reporting
system. Between 09:00 and 17:00 daily, positive MRSA
screens were verbally reported to nursing staff on rele-
vant wards and infection control teams. Turnaround
time was typically <24 h. All S aureus blood isolates were
identiﬁed initially by agglutination, using the
ProlexdBlue Staph Latex Kit (Pro-Lab, Richmond Hill,
Canada), and subsequently by a Vitek instrument, using
custom-made Staphylococcus sensitivity cards (Biomer-
ieux, Marcy l’Etoile, France).
Statistical analysis
Clinical epidemiology and secular trends
Comparisons between characteristics of MRSA and MSSA
and non-bacteraemic inpatient cohorts were made by c
2,
ManneWhitney U or independent samples t tests.
Univariate linear or logistic regression was used to model
associations between risk factors and rates of SAB. An
indirect standardised mortality ratio was calculated to
explore excess mortality in SAB, using all ARI inpatients
between 2006 and 2010 as the reference population, and
standardising by age, gender and specialty. Attributable
mortality, deﬁned as the excess mortality caused by
bacteraemia, was calculated using matched controls from
this inpatient reference group, as crude mortality rate in
controls minus crude mortality rate after bacteraemia.
Restricting analysis to the SAB cohort, determinants of
30-day mortality were explored by multivariate logistic
regression. A priori determinants of methicillin sensi-
tivity, month and demographics were included in
a multivariate model alongside signiﬁcant variables from
univariate analysis (p<0.10). Interaction terms were
generated for terms signiﬁcantly associated by Spearman
rank correlation but retained only where contributing to
model ﬁt. Competing hazards of inpatient mortality and
being discharged alive were further explored with
multivariate Cox-regression, with censoring at date of
discharge or death, respectively. Length of stay was
included as a time-dependent determinant of
mortality.
16
Secular trends in demographics, clinical characteristics
and outcomes in SAB cohorts were evaluated by logistic
or linear regressions, with month of isolate as the sole
explanatory variable. Trends in rates were examined
using Poisson regression, with Poisson distribution, log-
link function and the natural logarithm of AOBDs as the
offset. Difference in trends by admitting department was
assessed by an interaction term (department 3 month of
study). Multivariate Poisson regression models assessed
secular trends after adjusting for changes in case-mix.
Impacts of universal MRSA admission screening
We conducted intervention analyses to model the effects
of universal screening on SAB while controlling for hand
hygiene, antibiotic use and other dynamic explanatory
factors, using the Linear Transfer Function (LTF) iden-
tiﬁcation method suggested by Pankratz
39 After ensuring
stationary series, an initial transfer function model was
created, with six lags for all explanatory variables and an
autoregressive term of order 1. An iterative process of
eliminating non-signiﬁcant terms, and identifying
further autoregressive (AR) or moving average (MA)
terms for parts of the model remaining unexplained,
determined the most parsimonious LTF model. Model
parameters were estimated using unconditional least
squares and goodness-of-ﬁt evaluated by R
2. Finally,
diagnostic checks were used to determine whether
models adequately represented times-series data. These
included checking the statistical signiﬁcance of param-
eters, AR parameter stationarity and MA parameter
invertibility, and auto-correlation (ACF) and partial auto-
correlation (PACF) functions of residuals to ensure
remaining variability was random. Analysis of concurrent
trends in MSSA bacteraemia controlled for unidentiﬁed
aspects of care or infection control affecting the clinical
epidemiology of SAB.
Intervention analysis was conducted using SCA soft-
ware (Chicago, Illinois, USA, 1992) as described by Liu
and Hudak.
40 All other analyses were performed using
SPSS V.19.0 for windows.
RESULTS
Descriptive epidemiology
Cohort and rates of SAB
There were 430452 admissions to ARI between 2006 and
2010, representing 1430052 AOBDs (8% ICU). The
total number of days of follow-up was 7578805: median,
4 Lawes T, Edwards B, Lo ´pez-Lozano J-M, et al. BMJ Open 2012;2:e000797. doi:10.1136/bmjopen-2011-000797
Universal MRSA admission screening and Staphylococcus aureus bacteraemia181 days (range 180e355 days) for episodes of SAB, and
16 days (14 to 129 days) for other admissions.
Eight hundred and sixty-seven episodes of SAB were
identiﬁed in 795 patients, including 208 cases of MRSA
bacteraemia (24%). Sixty-two per cent of MRSA and 44%
of MSSA bacteraemia were HA (p<0.001). Overall preva-
lence density of SAB was 0.61/1000 AOBDs and HA inci-
dence density was 0.29/1000 AOBDs. Prevalence and HA
incidence were 2.1/1000 admissions and 3.0/1000 admis-
sions, respectively. Patients with SAB were more likely to be
male, older and admitted to medical or ICU settings than
the remainder inpatient population (table 1).
There were strong associations between rate of
SAB and age, days since admission and length of stay
(ﬁgure 2). Patients colonised with MRSA at admission
were 17 times more likely to develop HA MRSA bacter-
aemia (0.78 cases/1000 AOBDs) than those not colon-
ised (0.05 cases/1000 AOBDs) (crude OR (95% CI)¼
17.2 (15 to 20), p<0.001). Methicillin-resistant bacter-
aemia occurred more frequently in ICU or surgical
settings, older patients, following MRSA colonisation
and after prolonged or recent admission. Comparing
community with HA bacteraemia, there were no signiﬁ-
cant differences in demographics or rates of previous
admission in the past 12 months (41% vs 37%; p¼0.10).
Clinical outcomes
Inpatient and 30-day all-cause mortality rates after SAB
were 25% and 20%, respectively, and outcomes were
consistently worse than for patients without bacteraemia
(table 1). Inpatient mortality was over six times higher
than expected in the SAB cohort (standardised mortality
ratio 6.4, 95% CI 5.7 to 7.0). Attributable inpatient
mortality was 20% (MRSA 31%, MSSA 17%).
Methicillin resistance was associated with longer
length of stay and increased readmission rates. The
crude OR for mortality within 30 days of isolation of
MRSA versus MSSA was 2.15 (95% CI 1.50 to 3.08;
p<0.001). A ﬁnal multivariate logistic regression model
conﬁrmed age, month of study (secular trend) and HA
infection as independent risk factors for 30-day
mortality; however, after adjustment for these covariates,
methicillin resistance was not a signiﬁcant determinant
(table 2).
In a multivariate Cox-regression model, methicillin
resistance was associated with a nearly 50% increased
hazard of inpatient death (table 2), but there was no
signiﬁcant difference in discharge rate in survivors. Age,
duration of hospitalisation and HA infection were
independent predictors of hazard of inpatient death.
Secular trends
Trends in SAB and clinical outcomes
Prevalence density of all SAB declined from 0.73/1000
AOBDs to 0.50/1000 AOBDs ( 41%; p¼0.002 for trend)
between January 2006 and December 2010. Prevalence
density of MRSA bacteraemia fell 73% from 0.26 to 0.07/
1000 AOBDs (p<0.001) and HA incidence density 82%,
from 0.16 to 0.03/1000 AOBDs (p<0.001); however,
rates of MSSA bacteraemia were unchanged (ﬁgure 3).
An increasing proportion of MRSA bacteraemia
was associated with previous colonisation or infection
(table 3). Case-mix within the SAB cohort was otherwise
stable.
30-Day mortality after MRSA bacteraemia declined
from 37% to 13% (p¼0.027), but no signiﬁcant change
was observed in mortality after MSSA bacteraemia
(ﬁgure 3). By 2010, 90% of episodes of bacteraemia and
86% of associated inpatient deaths were attributable to
MSSA. These MRSA-speciﬁc declines closely correlated
with changes in rates of all MRSA or MSSA infection or
colonisation. By admitting department, declines in
MRSA prevalence density, HA incidence density and
mortality were signiﬁcantly steeper in ICU than medical
or surgical departments (p<0.05 for interaction term)
(ﬁgure 3).
Trends in inpatient case-mix
There were no signiﬁcant trends in admitting specialty
or gender among inpatients over the 5-year period.
Mean age of adults and all patients increased between
2006 and 2010 (+1.7, 95% CI +1.3 to +2.2 years, for all
patients; p<0.001), while mean length of stay ( 1.3,
95% CI  1.6 to  1.11 days; p<0.001) and weighted
average bed occupancy ( 2.6%, 95% CI  4.8% to
 0.4%; p¼0.021) declined (supplemental ﬁle 3).
Considering the associations noted earlier, these
changes represented opposing upward (increasing age)
and downward (reduced length of stay, bed occupancy)
pressures on rates of bacteraemia. Secular trend in
MRSA prevalence density (p¼0.03 for trend) and HA
incidence density (p¼0.01) remained signiﬁcant after
adjusting for these changes in case-mix in a multivariate
Poisson regression model.
Impacts of universal MRSA admission screening
Screening adherence and importation pressures
Forty-three per cent of all adult, non-obstetric overnight
admissions and 84% of eligible patients in high-risk
environments were screened prior to routine surveil-
lance. During universal surveillance, 87% of eligible
patients were screened (n¼86890). A target of 90%
adherence was achieved within 4 months of initiation
and sustained thereafter, excluding a special study
period in which trial of additional throat, perineum and
axillae swabs and discharge screening reduced patient
participation (ﬁgure 4).
MRSA prevalence at admission (importation pressure)
steadily declined during the period of universal surveil-
lance, averaging 3.1%, with 1.7% known to be previously
colonised or infected with MRSA. There was an increase
in episodes of MRSA bacteraemia preceded by screening
at admission (95% vs 81%; p¼0.008) and identiﬁed as
being colonised at admission (56% vs 38% of all
bacteraemia; p¼0.013; 30% vs 11% without history of
MRSA; p¼0.011) after introduction of universal surveil-
lance. Data from all hospitals involved in the pathﬁnder
study demonstrated that 78% of MRSA-positive patients
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Universal MRSA admission screening and Staphylococcus aureus bacteraemiawere successfully isolated or cohorted and 41% received
at least 1 day of decolonisation therapy.
29 Given that
<11% of admissions to ARI stayed for more than the
minimum 10 days required to identify MRSA from
screening, complete a full course of decolonisation and
obtain conﬁrmatory swabs, only 4.1% of MRSA-positive
patient were identiﬁed as being successfully decolonised
during the index admission (table 4).
29
Patient characteristics by study period
Case-mix remained stable between periods of selective
screening and universal admission screening (table 4).
However, there were signiﬁcant reductions in bed
occupancy and length of stay. There was an abrupt and
permanent decline in use of ‘4C’ and macrolide antibi-
otics within 3 months of the antibiotic stewardship
intervention (month 11 of universal screening).
Improvements in hand hygiene were suggested by
audited compliance but not by consumption of alcohol-
based hand-rub.
Time-series intervention analysis
In multivariate transfer function models, adjusting for
changes in other aspects of care and prior trends (table 5
and ﬁgure 5), universal screening was associated with
a 19% reduction in prevalence density (absolute change,
0.189 to 0.154 ( 0.035, 95% CI  0.049 to  0.021)/1000
AOBDs; p<0.001), a 29% reduction in HA incidence
density (0.100 to 0.071 ( 0.029, 95% CI  0.035 to
 0.023)/1000 AOBDs; p<0.001) and a 46% fall in
30-day mortality (34% to 18.4% ( 15.6%, 95% CI
 24.1% to  7.1%); p<0.001). Using targeted screening
as the comparison, during universal screening, the
number needed to screen to avoid one additional
episode of MRSA bacteraemia was 1978. Rates of
bacteraemia and 30-day mortality were also positively
associated with hospital-wide consumption of ﬂuo-
roquinolone and cephalosporin antibiotics 1e6 months
earlier. Assuming an average regimen of seven deﬁned
daily doses, the number needed to treat to cause one
additional case of MRSA bacteraemia was 179 for ceph-
alosporins and 204 for ﬂuoroquinolones. Compared
with forecasted consumption, reduction in the use of
these antibiotics following the ‘4C’ antibiotic steward-
ship intervention was projected to have reduced preva-
lence density of MRSA bacteraemia by 0.027 (0.15 to
0.039)/1000 AOBDs. No signiﬁcant relationships were
Figure 2 Rates of Staphylococcus aureus bacteraemia by age group, length of stay and days from admission. p<0.01 for all
linear regression lines. Note logarithmic scale for length of stay. Linear trend ﬁtted after logarithmic transformation. MRSA,
methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.
Table 2 Multivariate logistic and Cox-regression models of risk factors for 30-day mortality, inpatient mortality and discharge
alive
30 day mortality* Inpatient mortalityy Discharge alivez
OR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
MRSA 1.38 (0.93 to 2.06) 0.112 1.47 (1.09 to 1.98) 0.012 1.09 (0.89 to 1.33) 0.416
Gender (female) 1.41 (0.96 to 2.04) 0.075 1.18 (0.89 to 1.58) 0.244 1.06 (0.89 to 1.25) 0.536
Age (10/years) 1.79 (1.58 to 1.97) <0.001 1.42 (1.29 to 1.57) <0.001 0.86 (0.83 to 0.90) <0.001
Hospital-associated SAB 1.56 (1.08 to 2.26) 0.018 2.27 (1.67 to 2.27) <0.001 1.50 (1.26 to 1.80) <0.001
Secular trend per 3 months 0.87 (0.77 to 0.99) 0.028 0.92 (0.83 to 1.02) 0.094 ee
Length of stay (7/days)x ee 1.02 (1.01 to 1.03) <0.001 0.98 (0.97 to 0.98) <0.001
ICU admission ee ee 0.70 (0.59 to 1.00) 0.052
*Logistic regression for 30-day mortality. This model had good calibration (HosmereLemeshow goodness-of-ﬁt p¼0.93) and discrimination
(area under receiver operator characteristic curve ¼0.77).
yCox (proportional hazards) regression. Model c
2 (df) ¼115 (6); p<0.001.
zCox (proportional hazards) regression. Model c
2 (df) ¼265 (6); p<0.001.
xEntered as a time-dependent covariate.
ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; SAB, Staphylococcus aureus bacteraemia.
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Universal MRSA admission screening and Staphylococcus aureus bacteraemiaidentiﬁed with % hand-hygiene compliance, and
effect sizes for screening were comparable across all
departments. Final models explained 45%e68% of
variance, and in all models, residuals were randomly
distributed.
No signiﬁcant associations were found between
universal screening, hand hygiene or antibiotic use, and
rates of MSSA bacteraemia. The %SAB involving MRSA
fell by 52% (from 28.6% to 15.1% ( 13.5%, 95%
CI  20% to  7%); p¼0.014).
DISCUSSION
This retrospective cohort study identiﬁed a 41%
decrease in prevalence density of all SAB in an inpatient
population from Scotland between 2006 and 2010.
Secular trends were attributable to steep reductions in
MRSA bacteraemia. Introduction of a universal MRSA
admission screening programme was associated with
signiﬁcant reductions in rates of MRSA bacteraemia and
associated early mortality, while having no discernible
impact on burdens from MSSA bacteraemia. Ecological
and temporal associations between MRSA bacteraemia
and use of ﬂuoroquinolones and cephalosporins
suggested that a subsequent antibiotic stewardship
programme limiting use of these agents also contributed
to control of MRSA bloodstream infections.
Strengths and limitations
Analyses of risk factors for SAB acquisition and outcomes
were limited by a lack of information on comorbidities,
severity of sepsis, source control and clinical manage-
ment.
4 13 41 However, age has been shown to be an
appropriate proxy for comorbidity and risk of death,
13
and our estimates of attributable mortality approximate
those in more detailed analyses.
4 The effect of MRSA on
risk of 30-day mortality approximated estimates from
Figure 3 Secular trends in prevalence density and all-cause 30-day mortality after Staphylococcus aureus bacteraemia by
methicillin resistance and admitting department (MRSA only). Data aggregated in 3-month blocks. Lines represent results of trend
analysis, using Poisson regression with time (month) as sole explanatory variable. AOBDs, acute occupied bed days; ICU,
intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.
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Universal MRSA admission screening and Staphylococcus aureus bacteraemiaa previous meta-analysis,
17 and non-signiﬁcance may be
explained by a limited sample size.
Changes in strain distribution have been linked to
secular trends in invasive S aureus infections,
6 10 21 with
declines in epidemic strains predating decreases in
MRSA in the UK.
10 Reﬂecting national data,
10 regional
studies of MRSA infections from the same period iden-
tiﬁed signiﬁcant increase in EMRSA-15, with a reciprocal
decline in EMRSA-16.
42 43 Trends in strain may have
confounded, or mediated, the associations between
infection control measures and SAB epidemiology.
10
Universal MRSA admission screening was introduced
as part of an NHS Scotland Pathﬁnder Project,
precluding the use of cross-over or controlled trial
designs as elsewhere.
44 45 Data on isolation-days
captured, suggested as a measure of surveillance effec-
tiveness,
46 were also not available. We attempted to
minimise threats to internal validity common to quasi-
experimental studies of infection control measures.
22 38
A deﬁnition of bacteraemia based on blood isolates
rather than clinical suspicion made the study less
vulnerable to detection bias while follow-up to
a minimum of 2 weeks post-discharge prevented attrition
bias arising for changes in length of stay. An attempt to
identify and prevent selection and performance bias
was made by identifying and controlling for, changes in
case-mix, importation pressure,
47 48 and other aspects of
care,
22 before and after the intervention. Investigation of
concurrent trends in MSSA bacteraemia provided some
control for impacts of general improvements in infec-
tion control or clinical management and supports an
independent effect of screening on MRSA bacter-
aemia.
34 38 ARIMA techniques account for non-inde-
pendence of parameters and stochastic elements in time
series. This is convergent with understanding of the
spread of resistance and infectious disease within popu-
lations
38 and minimises the potential for regression to
the mean to account for trends.
Transfer function models including screening, antibi-
otic use and bed occupancy accounted for 45%e68% of
variation in rates of bacteraemia, suggesting unmeasured
factors affecting rates. Universal screening was one of
several sequentially implemented control measures for
MRSA in North East Scotland, including introduction
of environmental swabbing and disinfection (2001),
alcohol hand-gel (2002) and targeted admission
screening (2003). The lack of accurate data on alcohol-
based hand-gel consumption, and limited baseline data
before the national hand-hygiene campaign, may
explain a failure to identify signiﬁcant effects of hand-
improving hand hygiene
33 as described in other time-
series analyses.
34 35 Introduction of screening was likely
Table 3 Characteristics of Staphylococcus aureus bacteraemia, associated outcomes and frequencies of all S aureus isolates
by year of study: N (%), mean (SD) or median (IQR)
Year
p value*
2006
(n[218)
2007
(n[188)
2008
(n[151)
2009
(n[152)
2010
(n[158)
S aureus bacteraemia
N (%) involving <0.001
MSSA 156 (72) 140 (74) 100 (66) 121 (80) 142 (90)
MRSA 62 (28) 48 (26) 51 (34) 31 (20) 16 (10)
Demographics
Gender (female) (%) 66 (30) 62 (33) 55 (36) 55 (36) 49 (30) 0.603
Age (years) 57 (22) 56 (21) 58 (22) 56 (22) 57 (20) 0.744
Clinical characteristics
Hospital associated (%) 112 (51) 108 (60) 69 (46) 75 (50) 92 (58) 0.750
Previous S aureus bacteraemia,
any (%)
10 (5) 18 (10) 19 (13) 14 (10) 12 (8) 0.787
Previous MRSA colonisation or
infection (%)y
24 (39) 24 (50) 29 (57) 16 (52) 10 (63) 0.056
Admission within past 12 months (%) 134 (62) 101 (54) 92 (61) 96 (63) 99 (62) 0.503
Outcomes
30-day mortality (%) 52 (24) 39 (22) 31 (21) 27 (18) 24 (15) 0.013
Inhospital death (%) 63 (29) 45 (25) 34 (23) 34 (23) 33 (21) 0.045
Length of stay (days) 19 (10e41) 17 (7e36) 27 (12e36) 22 (12e44) 19 (12e42) 0.508
Readmission (#14 days) (%) 25 (17) 19 (14) 25 (22) 31 (27) 19 (16) 0.291
All S aureus infection/colonisations
N (%) involvingz <0.001
MSSA 1682 (72) 1532 (75) 1250 (74) 1416 (83) 1351 (90)
MRSA 638 (28) 510 (25) 448 (26) 289 (17) 151 (10)
*Linear and logistic regressions with month of study as sole explanatory variable.
yData presented for MRSA bacteraemia only.
zData available for adult non-obstetric patients 2006e2010. Counts represent non-duplicate isolates (one per patient per year).
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.
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Universal MRSA admission screening and Staphylococcus aureus bacteraemiato be associated with improved awareness among
healthcare workers and the public around MRSA, with
potential improvements in adherence to general infec-
tion control policy. Performance in infection control
may also have been inﬂuenced by internal audit of
MRSA screening. However, non-declining trends in
MSSA-suggested general infection control measures
were an inadequate explanation for MRSA-speciﬁc
declines.
Rates of MRSA colonisation, infection and bacter-
aemia, and effect sizes from intervention in the present
study are comparable to those described in previous
investigations of universal surveillance.
28 44e46 Findings
may be generalisable to other large public hospitals with
ICUs in high-income countries, with endemic MRSA and
relatively low rates of MRSA infection.
Comparison to literature
We identiﬁed a number of risk factors for developing
SAB and associated early mortality consistent with
previous ﬁndings, including older age,
3 41 3recent or
prolonged hospitalisation,
34 1history of colonisation or
infection,
47 colonisation on admissions,
47 48 and ICU
admissions.
9 Associations were signiﬁcantly stronger
for MRSA bacteraemia.
48 Despite two meta-analyses
suggesting an excess mortality in MRSA, compared with
MSSA bacteraemia,
15 17 there remains considerable
debate about the importance of methicillin resistance to
outcomes.
41 31 8Our ﬁndings suggest that much of the
increase in mortality associated with methicillin resis-
tance may be explained by infection of more vulnerable
patients,
13e18 often in the context of extended contact
with healthcare.
15 41
Reﬂecting the ﬁndings of an earlier study from
Oxfordshire, which found that MRSA-related disease was
responsible for increasing rates of SAB between 1997
and 2003,
3 our ﬁndings suggest that subsequent declines
have occurred, almost exclusively in MRSA-related
disease. An equivalent upward pressure on MSSA rates
has not been observed, consistent with observations
that MRSA appears to add to, rather than displace
MSSA infection.
21 These ﬁndings match experience
across the UK.
8
Evidence on the role of universal screening in reducing
all MRSA infections is conﬂicting,
28 30 44e46 49e52 and
beneﬁts may depend on target population, screening
technology and subsequent control interventions.
49 A
recent US study of routine surveillance for MRSA noted
Figure 4 Adherence to
methicillin-resistant
Staphylococcus aureus (MRSA)
admission testing during universal
surveillance (August 2008 to
December 2010). Special study
period (February 2010 to August
2010) involved a trial of axillae and
groin swabs.
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Universal MRSA admission screening and Staphylococcus aureus bacteraemiaa signiﬁcant downward trend in MRSA bacteraemia in
ICU but not in other hospital settings.
28 A second US
study found a decrease in hospital-wide MRSA but not
MSSA bacteraemia during universal screening.
46 In
agreement with these studies, we found that rates of
MRSA bacteraemia declined in parallel with all MRSA
infections,
50 53 and there was no reciprocal rise in
hospital-wide MSSA bacteraemia or infections.
46
Hospital-wide reductions in bacteraemia, of similar
magnitude to that seen in our study, were reported
following introduction of screening in intensive care
27 or
high-risk patients only.
26 However, we identiﬁed addi-
tional declines in both general and intensive care
settings, despite a baseline scenario involving routine
screening in high-risk patients. These ﬁndings also
contrast with those from a 1-year review of the pathﬁnder
study, which found that although declines in all MRSA
infections/colonisations were greater in intervention
Table 4 Characteristics preintervention and postintervention
Characteristic
Selective
screening only
Universal
admission
screening
Admission data
No. of all admissions 210745 209707
No. of AOBDs (at risk) 748569 681483
Mean (SD) length of stay in hospital, days 3.96 (0.23) 3.33 (0.51)
Bed occupancy (% all available beds occupied) 79 77
Case-mix
Mean (SD) age all patients, years 45.9 (0.45) 47.3 (0.57)
Mean (SD) age, ICU, medical and surgical adult services, years 55.3 (0.41) 56.4 (0.56)
Gender: n (%) of all admissions
Female 122538 (58) 120417 (57)
Male 88207 (42) 89290 (43)
Specialty, n (%) of all admissions
Surgical 84216 (40) 89808 (43)
Medical 65711 (31) 65098 (31)
ICU 3312 (2) 2954 (1)
Maternity 31862 (15) 29738 (14)
Paediatric/neonatal 24606 (12) 23147 (12)
MRSA screening, colonisation and all Staphylococcus aureus infections
N (%) of overnight admissionsy screened for MRSA 43158 (43) 86890 (87)
Number of overnight admission screened per 1000 AOBDs 58 128
Number (%) of overnight admissionsy positive for MRSA 2909 (3.5) 2694 (3.1)
Estimated n (%) of MRSA-positive patients isolated/cohorted No data 2101 (78)
Estimated n (%) of MRSA-positive patients receiving decolonisation therapy No data 1105 (41)
Estimated n (%) of MRSA-positive patients with conﬁrmed eradication No data 110 (4.1)
Other infection control measures
Hand hygiene (dispensed alcohol gel in litres/1000 AOBDs)z 38.1z 37.2
Mean (SD) monthly hand-hygiene compliance, % x 60.5% (12.3) 92.9% (3.7)
Mean (SD) monthly use of ‘4C’ and macrolide antibiotics (DDD/1000 AOBDs) 698 (79.4) 416 (107.7)
Monthly use of ‘4C’ and macrolide antibiotics as % of all antibiotic DDDs, % 66 37
Clinical burdens from S aureus bacteraemia
Prevalent MSSA bacteraemia (n) 353 306
Prevalent MRSA bacteraemia (n) 144 64
Hospital-associated incident MRSA bacteraemia (n) 89 29
Deaths within 30 days MSSA (n) 62 48
Deaths within 30 days MRSA (n) 51 12
Clinical burdens from other S aureus infections/colonisations
Prevalent MRSA infection (any) or colonisation (% admissions){ 1457 (1.0) 579 (0.4)
Prevalence density of any MRSA infection (cases/1000 AOBDs){ 2.25 (0.53) 0.96 (0.44)
Prevalent MSSA infection (any) or colonisation (% admissions){ 3932 (2.6) 3299 (2.1)
Prevalence density of any MSSA infection (cases/1000 AOBDs){ 5.86 (1.15) 5.49 (0.89)
‘4C’ antibiotics are ciproﬂoxacin (all ﬂuoroquinolones), cephalosporins, clindamycin, co-amoxiclav.
yAdult non-obstetric patients only.
zData available from April 2008 only (35 months).
xAverage ward compliance weighted by admissions as assessed by standardised audit methods integrating opportunity and technique from
January 2007.
{Data available for adult non-obstetric patients 2006e2010. Counts represent non-duplicate isolates (one per patient per year).
AOBDs, acute occupied bed days; DDDs, deﬁned daily doses; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus;
MSSA, methicillin-sensitive Staphylococcus aureus.
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Universal MRSA admission screening and Staphylococcus aureus bacteraemiathan control hospitals during universal screening, the
difference was non-signiﬁcant.
54 We note that this
comparison was limited by low numbers in control
hospitals, risks of contamination where control hospitals
were in the same NHS board, a short baseline and follow-
up period, and methods not accounting for non-inde-
pendence of observations in time-series and lagged
effects.
We are not aware of a previous time-series analysis
describing signiﬁcant impacts of universal screening on
% mortality following SAB. A lack of improvement in
mortality after MSSA bacteraemia did not suggest
general improvements in care. The increased proportion
of bacteraemia in those without history of MRSA iden-
tiﬁed as positive for MRSA at admission during universal
screening may have facilitated prompt initiation of
appropriate therapy. Other potential explanations
include increased awareness of invasive MRSA infection
in clinical staff with routine screening, greater marginal
beneﬁts of universal admission screening in ICU
settings
27 28 and changes in strain distribution.
42 43
Our ﬁndings suggest additional considerations in
assessing utility of universal surveillance. Patients
colonised at admission were at high risk of developing
HA MRSA bacteraemia, and early identiﬁcation of
colonised patients provides opportunities to reduce
invasive infection by decolonisation.
27 As elsewhere,
27
declines in HA infection were steeper than those in rates
including community-associated infection, coherent
with reductions in transmission. Similarly, decline in
importation pressure during universal surveillance
suggested interruption of connections between preva-
lence of MRSA in hospital and community populations,
focused in frequently admitted patients.
55e57 However,
approximately 50% of HA MRSA bacteraemia occurred
in patients not colonised at admission highlighting the
limitations in admission surveillance and the persistence
of cross-transmission.
58 Other lost opportunities to
prevent transmission may arise in practice, given the
respective 22% and 59% of MRSA-positive patients
not isolated or receiving any decolonisation therapy
during the pathﬁnder study. The latter is particularly
concerning as effective decolonisation may be a prereq-
uisite for cost-effectiveness of universal screening.
59
As in previous studies from the region,
35 36 we noted
the importance of antibiotic use in hospital in deter-
mining rates of all MRSA infections in the region.
Although both patient-level
37 and ecological associa-
tions
35 between ﬂuoroquinolone and cephalosporin use
and MRSA infection have been identiﬁed, we are not
aware of an experimental or quasi-experimental
study investigating impacts of limiting their use in the
control of MRSA bacteraemia speciﬁcally. Independent
effects of screening and antibiotic stewardship were of
Table 5 Multivariate transfer function models* for MRSA bacteraemia taking into account introduction of universal admission
screening and changes in other aspects of care (January 2006 to December 2010)
Term Ordery Parameterz (SE) T ratio p Value
(a) Prevalence density of MRSA bacteraemia (cases per 1000 AOBDs), R
2¼0.678
Universal MRSA admission screening intervention 3  0.0346 (0.0071)  4.89 <0.001
Cephalosporin use (DDDs/1000 AOBDs) 6 +0.0008 (0.0004) 2.03 0.046
Fluoroquinolone use (DDDs/1000 AOBDs) 5 +0.0007 (0.0002) +3.53 <0.001
MAx 4 +0.7602 (0.0932) +8.15 <0.001
AR{ 6  0.3100 (0.1309)  2.37 0.019
(b) Hospital-associated incidence density of MRSA bacteraemia (cases per 1000 AOBDs), R
2¼0.648
Universal MRSA admission screening intervention 3  0.0290 (0.0032)  8.92 <0.001
Fluoroquinolone use (DDDs/1000 AOBDs) 5 +0.0006 (0.0001) 63.93 <0.001
MA1x 2 +0.5801 (0.1273) 4.56 <0.001
MA2x 3 +0.2960 (0.1384) 2.14 0.032
MA3x 5 +0.3028 (0.1298) 2.33 0.014
(c) % SABs involving MRSA (%), R
2¼0.504
Universal MRSA admission screening intervention 3  13.490 (3.322)  4.06 <0.001
Fluoroquinolone use (DDDs/1000 AOBDs) 5 +0.097 (0.047) 2.06 0.042
Bed occupancy, %** 2 +0.201 (0.094) 2.14 0.032
MAx 9  0.519 (0.115)  4.51 <0.001
(d) 30-day mortality (%) after MRSA bacteraemia, R
2¼0.448
Universal MRSA admission screening intervention 0  15.615 (4.349)  3.59 <0.001
Fluoroquinolone use (DDDs/1000 AOBDs) 1 +0.222 (0.023) 9.54 <0.001
MAx 8  0.306 (0.108)  2.85 0.005
*All series stationary before model identiﬁcation.
yDelay necessary to observe the effect (in months).
zSize and direction of effect.
xMA, moving average term representing abrupt changes in bacteraemia rates or mortality in immediate future.
{AR, autoregressive term representing past values of bacteraemia rates or mortality.
**% Bed occupancy, average bed occupancy weighted by admitting department, by month.
AOBDs, acute occupied bed days; DDDs, deﬁned daily doses; MRSA, methicillin-resistant Staphylococcus aureus; SAB, Staphylococcus
aureus bacteraemia.
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roles in the control of both invasive and other MRSA
infections.
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Implications for practice, policy and research
Our study suggests that universal admission screening
for MRSA may have an important effect on rates of
MRSA bacteraemia and associated mortality, beyond
selective screening of high-risk patients. However, there
remains debate around the cost-effectiveness of universal
surveillance in comparison to alternative control
measures,
51 59e63 risks of chlorhexidine resistance with
widespread decolonisation
9 and opportunity costs or
unintended harms associated with isolation.
64 Subse-
quent to the pathﬁnder study, NHS Scotland has
suggested hospital-wide targeted surveillance based on
clinical risk assessment as a minimum standard.
65 This is
convergent with an emerging consensus that admission
screening based on clinical prediction rules may offer
a more efﬁcient and pragmatic approach outside the
populations with high prevalence of MRSA.
49 63 66 Our
ﬁndings suggest the need to consider the greater
marginal beneﬁts in preventing bacteraemia and asso-
ciated mortality, which impose disproportional health-
care and wider societal costs.
67 Considered alongside
subsequent experience of low adherence to clinical risk
assessment-based screening in NHS Grampian, we suggest
the need to re-evaluate the beneﬁts of universal
screening in Scotland. Irrespective of the chosen
strategy, as the additional effects of antibiotic steward-
ship in this study and effects of bed occupancy suggest,
beneﬁts of admission screening will be optimised where
integrated with a broader package of infection preven-
tion and control measures.
28 49 58
The concentration of both MRSA and MSSA blood-
stream infections in susceptible patient groups with
higher levels of healthcare contact suggests that some
measures successfully limiting invasive MRSA infections
may be generalisable to control of all SAB. A more
rigorous approach to identify and limit iatrogenic
sources of bacteraemia, including peripheral or central
catheters,
41 48 68 is required. Screening for MSSA with
isolation and decolonisation has been suggested for
selected high-risk patients.
69
Figure 5 Observed trends and multivariate transfer model predictions (sum of lagged explanatory variables) for prevalence
density, hospital-associated (HA) incidence density, 30-day mortality in methicillin-resistant Staphylococcus aureus (MRSA)
bacteraemia and % Staphylococcus aureus bacteraemia (SAB) involving MRSA. CL, conﬁdence limit.
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Universal MRSA admission screening and Staphylococcus aureus bacteraemiaEqually, strategies are required that account for the
distinct epidemiology of MSSA and MRSA bacteraemia.
In contrast to MRSA, the majority of MSSA bacteraemia
in this study were community associated and occurred in
younger patients. Targeted measures are required to
prevent invasive infection in at-risk groups, including IV
drug users,
41 70 surgical, diabetic and renal patients.
69 71
Given the role of social and risk-networks in sustaining
S aureus transmission,
70 broadening control of SAB to
the community is likely to require the commitment of
multiple agencies and healthcare providers.
Changes in virulence of MSSA and MRSA may account
for divergence in trends in outcomes.
13 Genetic
sequencing or typing could be used to quantify the
contribution of clonal expansion to recent trends in SAB
epidemiology. A recent multicentre study found large
variation in management of SAB in the UK and called
for high-level evidence to deﬁne optimal care.
41 Future
research and guidelines should consider both MSSA and
MRSA bacteraemia.
In summary, this study described decreasing trends in
SAB following a decade of infection control policies
focusing on MRSA. Expansion from targeted to
universal MRSA admission screening was associated with
important reductions in MRSA bacteraemia when
combined with isolation and decolonisation. However,
ﬁndings also highlighted the need for strategies to
reduce clinical burdens from invasive MSSA infection if
progress towards national targets for SAB is to be
sustained.
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